Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients

• Anant A. Agrawal,
• Michael Seiler,
• Lindsey T. Brinton,
• Rose Mantel,
• Rosa Lapalombella,
• Jennifer A. Woyach,
• Amy J. Johnson,
• Ping Zhu,
• Markus Warmuth,
• Lihua Yu,
• John C. Byrd,
• Peter G. Smith,
• James S. Blachly,
• Silvia Buonamici

Affiliations

Anant A. Agrawal

H3 Biomedicine, Inc., Cambridge, MA

Michael Seiler

H3 Biomedicine, Inc., Cambridge, MA

Lindsey T. Brinton

Ohio State University Comprehensive Cancer Center, Columbus, OH

Rose Mantel

Ohio State University Comprehensive Cancer Center, Columbus, OH

Rosa Lapalombella

Ohio State University Comprehensive Cancer Center, Columbus, OH

Jennifer A. Woyach

Ohio State University Comprehensive Cancer Center, Columbus, OH

Amy J. Johnson

Ohio State University Comprehensive Cancer Center, Columbus, OH

Ping Zhu

H3 Biomedicine, Inc., Cambridge, MA

Markus Warmuth

H3 Biomedicine, Inc., Cambridge, MA

Lihua Yu

H3 Biomedicine, Inc., Cambridge, MA

John C. Byrd

Ohio State University Comprehensive Cancer Center, Columbus, OH

Peter G. Smith

H3 Biomedicine, Inc., Cambridge, MA

James S. Blachly

Ohio State University Comprehensive Cancer Center, Columbus, OH

Silvia Buonamici

H3 Biomedicine, Inc., Cambridge, MA; Silvia Buonamici, H3 Biomedicine, Inc., 300 Technology Sq, Cambridge, MA 02139;